New developments in gout

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 304-309

  Harrold, Leslie ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

gout; guidelines; interleukin 1b; urate lowering therapy

Indexed keywords

ALLOPURINOL; ARHALOFENATE; CANAKINUMAB; LESINURAD; PEGLOTICASE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE ACETONIDE; ULODESINE;

CREATININE BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; GOUT; HUMAN; HYPERURICEMIA; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; PATIENT EDUCATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SELF CARE; SIDE EFFECT; TREATMENT DURATION;

ACUTE DISEASE; CHRONIC DISEASE; GOUT; GOUT SUPPRESSANTS; HUMANS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; URICOSURIC AGENTS;

EID: 84875898357     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835fd5e5     Document Type: Review

References (57)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26-35.
2. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising J Rheumatol 2002; 29:2403-2406.
3. Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: the Health Professionals' Follow-Up Study. Kidney Int 2003; 64:1022-1026.
4. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31:1582-1587.
5. Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Therap 2003; 25:1593-1617.
6. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskeletal Disord 2011; 12:103.
7. Keith MP, Gilliland WR. Updates in the management of gout. Am J Med 2007; 120:221-224.
8. Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. Am J Med 2012; 125:499-504.
9. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324.
10. Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011; 123 (6 Suppl 1):3-36.
11. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford, England) 2007; 46:1372-1374.
12. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47:356-360.
13. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36:1273-1282.
14. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321-325.
15. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66:1056-1058.
16. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout J Rheumatol 2001; 28:577-580.
17. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout Arthritis Rheum 2007; 57:1324-1328.
18. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005; 174:5016-5023.
19. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
20. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-856.
21. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011; 4:39-49.
22. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
23. Schumacher H ER, Birbara C, et al. Rilonacept for prevention of gout flares associated with uric acid-lowering therapy: response rate across three phase 3 clinical trials. Arthritis Rheum 2011; 63 (S10):S1024.
24. Schumacher HR Jr, EVans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 2012; 64:1462-1470.
25. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839-1848.
26. So A, Alten R, Schumacher H, et al. Long-term safety of canakinumab in patients with gout arthritis. Arthritis Rheum 2012; 64 (S10):S144.
27. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711-720.
28. Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol 2012; 39:1450-1457.
29. Becker M, Baraf H, Yood R, et al. Clinical efficacy outcomes with up to 3 years of pegloticase treatment for refractory chronic gout. Arthritis Rheum 2012; 64 (S10):S159.
30. Becker MA, Baraf HSB, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2012. Published online first: 10 November 2012.
31. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011; 71:1413-1439.
32. Sundy J, Perez Ruiz F, Krishnan E, et al. Efficacy and safety of Lesinurad (RDEA594), A novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: preliminary results the randomized, double-blind, placebo-controlled, phase 2B extension study. Arthritis Rheum 2011; 63 (S10):S1021.
33. Choi Y, Larroca V, Lucman A, et al. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties. Arthritis Rheum 2012; 64 (S10):S1632.
34. Hollister A, Maetzel A, BeckerM, et al. Ulodesine (BCS4208) long-termsafety when added to allopurinol in the chronic management of gout: a Phase 2 24-week blinded safety extension and vaccine challenge study. Arthritis Rheum 2012; 64 (S10):S150.
35. Noveck RJ, Wang Z, Forsthoefel A, et al. Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout. Presented at the 2012 Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, November 9-4, 2012 Washington, D.C.
36. Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006; 119:800.
37. Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012; 71:1448-1453.
38. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093-1103.
39. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52:283-289.
40. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277-1281.
41. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010; 22:165-172.
42. Zhang Y, Neogi T, Chen C, et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum 2012; 64:4004-4011.
43. Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford, England) 2010; 49:2391-2399.
44. Harrold LR, Mazor KM, Velten S, et al. Patients and providers view gout differently: a qualitative study. Chronic Illn 2010; 6:263-271.
45. Harrold LR, Mazor KM, Peterson D, et al. Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskeletal Disord 2012; 13:180.
46. Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care A review of current practice and proposed guidelines. Clin Rheumatol 2000; 19:21-25.
47. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012; 71:1490-1495.
48. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with uratelowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11:R46.
49. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008; 67:609-613.
50. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31:1575-1581.
51. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009; 38:396-402.
52. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81:925-934.
53. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28:437-443.
54. Goldfien R, Ng M, Yip G, et al. Feasibility of using a pharmacist-based gout management clinic to improve serum uric acid in gout patients in a large prepaid health plan. Arthritis Rheum 2012; 64 (S10):S817.
55. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2012. Published online June 7, 2012 http://ard.bmj.com/content/early/ 2012/06/06/annrheumdis-2012-201676.
56. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64:1431-1446.
57. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 64:1447-1461.